Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | FNTA | P49354 | 1/20 | 0.61 |
| ▸ | FNTB | P49356 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11606568 | 0.92 | MAPT (0.55) | L3MBTL1MAPTFNTAFNTBKMT2A | |
| SCHEMBL6784815 | 0.85 | CYP19A1 (0.63) | MAPTFNTAFNTBKMT2ANAPRT | |
| SCHEMBL1515767 | 0.85 | NAPRT (0.68) | L3MBTL1MAPTKMT2ANAPRTMEN1 | |
| SCHEMBL11825208 | 0.84 | TSHR (0.62) | L3MBTL1MAPTKMT2AMEN1USP2 | |
| SCHEMBL6282620 | 0.84 | GAA (0.57) | KMT2ANAPRTMEN1LMNAIDO1 | |
| SCHEMBL6283045 | 0.84 | IDO1 (0.58) | L3MBTL1KMT2ANAPRTALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL27958148 | 0.83 | NAPRT (0.66) | L3MBTL1MAPTKMT2ANAPRTMEN1 | |
| SCHEMBL6282383 | 0.83 | NPC1 (0.58) | FNTAFNTBKMT2ANAPRTMEN1 | |
| SCHEMBL7538532 | 0.83 | KMT2A (0.53) | MAPTFNTAFNTBKMT2AMEN1 | |
| SCHEMBL17672056 | 0.83 | NAPRT (0.65) | KMT2ANAPRTMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272036-A1 | Ketones | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | US | disclosed |
| US-6962933-B1 | Method for inhibiting p38 MAP kinase or TNF-α production using a 1,3-thiazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-08 | — | — | US | disclosed |
| CN-1681763-A | Chemical compounds | ASTRAZENECA AB (SE) | 2005-10-12 | — | — | CN | disclosed |
| EP-1549600-A1 | KETONES | AstraZeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| US-20040097555-A1 | Concomitant drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| WO-2004011410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-02-05 | — | — | WO | disclosed |
| EP-1027050-B1 | 1,3-THIAZOLES AS ADENOSINE A3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ALLERGY, ASTHMA AND DIABETES | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-01-14 | — | — | EP | disclosed |
| EP-1354603-A1 | CONCOMITANT DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| US-6620825-B1 | 1,3-Azole compound substituted by pyridyl; administering as antiasthmatic, antiinflammatory or antiallergen agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-09-16 | — | — | US | disclosed |
| US-6436966-B1 | Adenosine A3 receptor antagonists | TAKEDA CHEMICAL IND., LTD. (JP) | 2002-08-20 | — | — | US | disclosed |
| EP-1205478-A1 | p38MAP KINASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2002-05-15 | — | — | EP | disclosed |
| EP-1027050-A2 | ADENOSINE A3 RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999021555-A2 | ADENOSINE A3 RECEPTOR ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-05-06 | — | — | WO | disclosed |
| US-4605656-A | Pyridine and pyrazine oxime compounds as fungicides | HOFFMANN-LA ROCHE INC. (US) | 1986-08-12 | — | — | US | disclosed |
| EP-0049854-B1 | PYRIDINE AND PYRAZINE DERIVATIVES, PREPARATION OF THESE COMPOUNDS, FUNGICIDAL AGENTS CONTAINING THESE COMPOUNDS AS ACTIVE INGREDIENTS, AND THE USE OF SUCH COMPOUNDS OR AGENTS AS FUNGICIDES IN AGRICULTURE AND IN HORTICULTURE | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1985-01-16 | — | — | EP | disclosed |
| EP-0049854-A2 | Pyridine and pyrazine derivatives, preparation of these compounds, fungicidal agents containing these compounds as active ingredients, and the use of such compounds or agents as fungicides in agriculture and in horticulture | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | L3MBTL1 4484/4885MAPT 2844/4885FNTA 1484/4885 |
| US-20040097555-A1 | Concomitant drugs | TNF, CHUK, CNKSR1 | L3MBTL1 4739/4885MAPT 2113/4885FNTA 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.